NasdaqGS:EXELBiotechs
Should New ASCO Colorectal Cancer Data on Zanzalintinib Reshape Exelixis' (EXEL) Investment Narrative?
Exelixis recently outlined a packed schedule of presentations at the 2026 ASCO Annual Meeting in Chicago, showcasing new clinical analyses for its approved cancer drug CABOMETYX and its investigational kinase inhibitor zanzalintinib across multiple late-stage trials and tumor types.
These data, including pivotal phase 3 results in metastatic colorectal cancer and further evidence for CABOMETYX’s role across difficult-to-treat tumors, could materially influence how investors view the depth...